Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 101 to 110 of 281 total matches.
Rimegepant (Nurtec ODT) for Acute Treatment of Migraine
The Medical Letter on Drugs and Therapeutics • May 04, 2020 (Issue 1597)
not have vasoconstrictive effects and is not contraindicated
for use in patients with vascular disease.
DRUG INTERACTIONS ...
The FDA has approved an orally disintegrating tablet
(ODT) formulation of rimegepant (Nurtec ODT –
Biohaven), a small-molecule calcitonin gene-related
peptide (CGRP) receptor antagonist ("gepant"), for
acute treatment of migraine with or without aura
in adults. Rimegepant is the second oral gepant to
become available in the US; ubrogepant (Ubrelvy),
which is approved for the same indication, was the
first. Four parenteral CGRP antagonists, erenumab
(Aimovig), fremanezumab (Ajovy), galcanezumab
(Emgality), and eptinezumab (Vyepti), are approved
for prevention of...
A Donepezil Patch (Adlarity) for Alzheimer's Disease (online only)
The Medical Letter on Drugs and Therapeutics • Aug 08, 2022 (Issue 1656)
, and skin laceration.
DRUG INTERACTIONS — Use of donepezil with other
drugs that have cholinergic effects ...
A once-weekly transdermal formulation of the
acetylcholinesterase inhibitor donepezil (Adlarity –
Corium) has been approved by the FDA for
treatment of mild, moderate, and severe Alzheimer's
disease (AD) dementia. Donepezil is the second
acetylcholinesterase inhibitor to become available in
a transdermal formulation; transdermal rivastigmine
(Exelon Patch), which is applied once daily, has been
available for years for the same indication. Donepezil
is also available in oral formulations (Aricept, and
generics) for treatment of AD dementia.
Lefamulin (Xenleta) for Community-Acquired Bacterial Pneumonia
The Medical Letter on Drugs and Therapeutics • Sep 23, 2019 (Issue 1581)
by CYP3A4 and may interact with drugs
that are substrates or strong or moderate inhibitors or inducers ...
Lefamulin (Xenleta – Nabriva), a semisynthetic
pleuromutilin antibiotic, has been approved by the
FDA for IV and oral treatment of community-acquired
bacterial pneumonia (CABP) in adults. It is the first
systemic pleuromutilin antibiotic to be approved in the
US; retapamulin (Altabax), a 1% topical ointment for
treatment of impetigo, was approved in 2007.
Two Vonoprazan Combinations (Voquezna) for H. pylori
The Medical Letter on Drugs and Therapeutics • Oct 31, 2022 (Issue 1662)
with coronary artery disease.9
DRUG INTERACTIONS — Vonoprazan may decrease
serum concentrations of drugs ...
The FDA has approved vonoprazan, a potassium-competitive
acid blocker, copackaged with amoxicillin
(Voquezna Dual Pak – Phathom) and with amoxicillin
and clarithromycin (Voquezna Triple Pak) for
treatment of Helicobacter pylori infection in adults.
Vonoprazan is the first potassium-competitive acid
blocker to be approved in the US. It has been available
in Japan for treatment of various acid-related
disorders since 2014. Vonoprazan is not available
alone in the US.
Paxlovid for Treatment of COVID-19
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022 (Issue 1642)
dysgeusia, diarrhea, hypertension, and myalgia.
DRUG INTERACTIONS ― Both nirmatrelvir and
ritonavir ...
On December 22, 2021, the FDA issued an Emergency
Use Authorization (EUA) for the investigational
antiviral drug nirmatrelvir copackaged with the HIV-1
protease inhibitor ritonavir (Paxlovid – Pfizer) for
oral treatment of mild to moderate COVID-19 in
outpatients ≥12 years old who weigh at least 40 kg
and are at high risk of progressing to severe disease,
including hospitalization or death. Paxlovid was the
first oral antiviral drug to be authorized in the US for
treatment of COVID-19; Merck's oral antiviral drug
molnupiravir was granted an EUA for treatment of
COVID-19 on...
Tirzepatide (Zepbound) for Chronic Weight Management
The Medical Letter on Drugs and Therapeutics • Dec 25, 2023 (Issue 1692)
, and
diabetic retinopathy complications can occur.
Drug Interactions: Tirzepatide delays gastric emptying ...
The injectable glucose-dependent insulinotropic
polypeptide (GIP)/glucagon-like peptide-1 (GLP-1)
receptor agonist tirzepatide, which was approved by
the FDA as Mounjaro for treatment of type 2 diabetes
in 2022, has now been approved as Zepbound (Lilly)
for chronic weight management in adults who have
a BMI ≥30 kg/m2 or a BMI ≥27 kg/m2 and at least
one weight-related comorbidity. The injectable
GLP-1 receptor agonists liraglutide (Saxenda) and
semaglutide (Wegovy) are approved for chronic
weight management in patients ≥12 years...
Med Lett Drugs Ther. 2023 Dec 25;65(1692):205-7 doi:10.58347/tml.2023.1692c | Show Introduction Hide Introduction
Olopatadine/Mometasone (Ryaltris) for Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023 (Issue 1668)
was
reported rarely.
Drug Interactions: Strong CYP3A4 inhibitors may increase
serum concentrations ...
The FDA has approved Ryaltris (Hikma), a fixed-dose
combination nasal spray containing the H1-antihistamine olopatadine hydrochloride (Patanase,
and generics) and the corticosteroid mometasone
furoate (Nasonex 24 HR Allergy, and generics), for
treatment of seasonal allergic rhinitis symptoms
in persons ≥12 years old. Ryaltris is the second
intranasal antihistamine/corticosteroid combination
to be approved for this indication; azelastine 0.1%/fluticasone propionate (Dymista, and generics), which
is approved for use in persons ≥6 years old, was the
first. Both products are available...
Med Lett Drugs Ther. 2023 Jan 23;65(1668):12-4 doi:10.58347/tml.2023.1668c | Show Introduction Hide Introduction
Olutasidenib (Rezlidhia) for Acute Myeloid Leukemia (online only)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
with olutasidenib
and for at least 2 weeks after the last dose.
DRUG INTERACTIONS — Olutasidenib is a CYP3A ...
Olutasidenib (Rezlidhia – Rigel), an oral isocitrate
dehydrogenase-1 (IDH1) inhibitor, has been
approved by the FDA for treatment of relapsed or
refractory acute myeloid leukemia (AML) in adults
with a susceptible IDH1 mutation. It is the second
drug that targets cancer metabolism to be approved
for this indication; ivosidenib (Tibsovo) was
approved in 2022.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):e58-9 doi:10.58347/tml.2023.1673e | Show Introduction Hide Introduction
Capmatinib (Tabrecta) for NSCLC (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
photosensitivity; patients should limit
direct ultraviolet exposure during treatment.
DRUG INTERACTIONS ...
The FDA has granted regular approval to the oral
kinase inhibitor capmatinib (Tabrecta – Novartis) for
treatment of metastatic non-small cell lung cancer
(NSCLC) in adults whose tumors have a mutation that
leads to mesenchymal-epithelial transition (MET)
exon 14 skipping. MET exon 14 skipping mutations
occur in 3-4% of NSCLC cases. The drug received
accelerated approval for the same indication in 2020
based on initial overall response rates and duration
of response.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e65-6 doi:10.58347/tml.2023.1674d | Show Introduction Hide Introduction
In Brief: A New Indication for Pemigatinib (Pemazyre) (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
, every
2 months for the first 6 months, and every 3 months
thereafter.
DRUG INTERACTIONS — Pemigatinib ...
The oral kinase inhibitor pemigatinib (Pemazyre –
Incyte) has been approved by the FDA for treatment
of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth
factor receptor 1 (FGFR1) rearrangements. It is the
first targeted therapy to be approved in the US for this
indication. The drug received accelerated approval
from the FDA in 2020 for treatment of adults with
previously treated, unresectable, locally advanced or
metastatic cholangiocarcinoma with FGFR2 fusions
or other rearrangements.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e71-2 doi:10.58347/tml.2023.1674g | Show Introduction Hide Introduction